203 related articles for article (PubMed ID: 33620088)
1. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
Veldman J; Alsada ZND; van den Berg A; Plattel WJ; Diepstra A; Visser L
Br J Haematol; 2021 May; 193(3):506-514. PubMed ID: 33620088
[TBL] [Abstract][Full Text] [Related]
2. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I
PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Koh YW; Han JH; Yoon DH; Suh C; Huh J
Ann Hematol; 2017 Nov; 96(11):1883-1890. PubMed ID: 28842748
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.
Pelland K; Mathews S; Kamath A; Cohen P; Hudnall SD; Cotta CV; Xu ML
Appl Immunohistochem Mol Morphol; 2018; 26(10):e101-e106. PubMed ID: 29189264
[TBL] [Abstract][Full Text] [Related]
5. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
9. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Volaric A; Bacchi CE; Gru AA
Am J Surg Pathol; 2020 Oct; 44(10):1353-1366. PubMed ID: 32649320
[TBL] [Abstract][Full Text] [Related]
11. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
Feng X; Luo X; Yang Y; Fan Y; Ye Q
Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
[TBL] [Abstract][Full Text] [Related]
12. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
14. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
Özdemir S; Ton Ö; Kabukcuoğlu F
Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
[TBL] [Abstract][Full Text] [Related]
16. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
17. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Liu Y; Huang R; Liu L; Meng Y; Liu X
Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
[TBL] [Abstract][Full Text] [Related]
19. Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.
Kohno K; Sakakibara A; Iwakoshi A; Hasegawa M; Adachi S; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
Pathol Int; 2020 Feb; 70(2):108-115. PubMed ID: 31894892
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]